The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | CTCs as a prognostic biomarker in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the growing clinical relevance of circulating tumour cells (CTCs) in multiple myeloma. He highlights recent evidence supporting CTCs as an independent prognostic biomarker, their ability to improve current risk models, and how standardized cut-offs could facilitate incorporation into future diagnostic and staging pathways. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
